PU.1 affects proliferation of the human acute myeloid leukemia U937 cell line by directly regulating MEIS1

被引:6
|
作者
Zhou, Jing [1 ,2 ]
Zhang, Xiaofeng [3 ]
Wang, Yuhua [2 ,4 ]
Guan, Yinghui [5 ]
机构
[1] Chinese Acad Sci, Beijing Inst Genom, Lab Genome Variat & Precis Biomed, Beijing 100101, Peoples R China
[2] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA 02142 USA
[3] Univ Massachusetts, Dept Chem, Boston, MA 02125 USA
[4] Shanghai Jiao Tong Univ, Sch Med, Coll Stomatol, Shanghai Key Lab Stomatol,Dept Prosthodont,People, Shanghai 200011, Peoples R China
[5] Jilin Univ, Resp Dept, Branch 2, Hosp 1, Changchun 130021, Jilin, Peoples R China
基金
中国国家自然科学基金;
关键词
PU.1; MEIS1; leukemia; transcription; TRANSCRIPTION FACTOR PU.1; HEMATOPOIETIC PROGENITORS; COMMITMENT; EXPRESSION; MUTATIONS; TARGETS; HOXA9; FATE;
D O I
10.3892/ol.2015.3404
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The transcription factor PU.1 is a member of the ETS family, which is expressed in a wide variety of hematopoietic lineages. Accumulating evidence has indicated that PU.1 plays a key role in hematopoiesis, and reduced expression of PU.1 leads to the pathogenesis of human myeloid leukemia. As a multi-functional factor, PU.1 is also required for mixed lineage leukemia (MLL) stem cell potential and the development of MLL. However, the function of PU.1 in human non-MLL leukemia and its molecular mechanism remains poorly understood. In the present study, PU.1 siRNA was demonstrated to efficiently inhibit the transcription level of oncogene MEIS1 in the human acute myeloid non-MLL leukemia U937 cell line. In addition, PU.1, as a positive regulator of MEIS1, performed a crucial role in maintaining cell proliferation. Using electrophoretic mobility shift assay, chromatin immunoprecipitation analysis and luciferase reporter assay, previously unexplored evidence that PU.1 activated the MEIS1 promoter through a conserved binding motif in vitro and in vivo was further defined. Overall, the present study provides insight into the molecular mechanism of the contribution of PU.1 to the pathogenesis of non-MLL U937 cells, which is mediated by direct regulation of MEIS1 transcription. The present data reveal the possibility of developing an alternative therapy for non-MLL leukemia by targeting PU.1-mediated MEIS1 gene activation.
引用
收藏
页码:1912 / 1918
页数:7
相关论文
共 50 条
  • [21] High expression of Inc-CRNDE presents as a biomarker for acute myeloid leukemia and promotes the malignant progression in acute myeloid leukemia cell line U937
    Wang, Y.
    Zhou, Q.
    Ma, J. -J.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2018, 22 (03) : 763 - 770
  • [22] PU.1 (SPI-1) expression in human acute leukemia
    Voso, MT
    Chiusolo, P
    Hohaus, S
    Serra, FG
    Sica, S
    Piccirillo, N
    Tenen, DG
    Leone, G
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 144 - 144
  • [23] The PU.1 transcription factor induces cyclin D2 expression in U937 cells
    L Vicari
    A Eramo
    L Manzella
    L Malaguarnera
    G Iannolo
    M Gulisano
    R De Maria
    A Messina
    P Vigneri
    Leukemia, 2006, 20 : 2208 - 2210
  • [24] The PU.1 transcription factor induces cyclin D2 expression in U937 cells
    Vicari, L.
    Eramo, A.
    Manzella, L.
    Malaguarnera, L.
    Iannolo, G.
    Gulisano, M.
    De Maria, R.
    Messina, A.
    Vigneri, P.
    LEUKEMIA, 2006, 20 (12) : 2208 - 2210
  • [25] INHIBITION OF THE MYELOID MASTER REGULATOR PU.1 AS A THERAPEUTIC STRATEGY IN ACUTE MYELOID LEUKEMIA
    Antony-Debre, I.
    Leite, J.
    Paul, A.
    Mitchell, K.
    Kim, H. M.
    Huang, K.
    Kumar, A.
    Farahat, A. A.
    Bartholdy, B.
    Narayanagari, S. -R.
    Carvajal, L. A.
    Chen, J.
    Ambesi-Impiombato, A.
    Ferrando, A. A.
    Mantzaris, I.
    Gavathiotis, E.
    Verma, A.
    Will, B.
    Boykin, D. W.
    Wilson, W. D.
    Poon, G. M. K.
    Steidl, U.
    HAEMATOLOGICA, 2017, 102 : 18 - 18
  • [26] INHIBITION OF THE MYELOID MASTER REGULATOR PU.1 AS A THERAPEUTIC STRATEGY IN ACUTE MYELOID LEUKEMIA
    Antony-Debre, Ileana
    Leite, Joana
    Paul, Ananya
    Mitchell, Kelly
    Kim, Hye Mi
    Huang, Kenneth
    Kumar, Arvind
    Farahat, Abdelbasset A.
    Bartholdy, Boris
    Narayanagari, Swathi-Rao
    Carvajal, Luis A.
    Chen, Jiahao
    Ambesi-Impiombato, Alberto
    Ferrando, Adolfo A.
    Mantzaris, Ioannis
    Gavathiotis, Evripidis
    Verma, Amit
    Will, Britta
    Boykin, David W.
    Wilson, W. David
    Poon, Gregory M. K.
    Steidl, Ulrich
    EXPERIMENTAL HEMATOLOGY, 2017, 53 : S133 - S133
  • [27] MEIS1, PREP1, and PBX4 Are Differentially Expressed in Acute Lymphoblastic Leukemia: Association of MEIS1 Expression with Higher Proliferation and Chemotherapy Resistance
    Judith A Rosales-Aviña
    Jorge Torres-Flores
    Adriana Aguilar-Lemarroy
    Carmen Gurrola-Díaz
    Georgina Hernández-Flores
    Pablo C Ortiz-Lazareno
    José M Lerma-Díaz
    Ruth de Celis
    Óscar González-Ramella
    Esperanza Barrera-Chaires
    Alejandro Bravo-Cuellar
    Luis F Jave-Suárez
    Journal of Experimental & Clinical Cancer Research, 30
  • [28] MEIS1, PREP1, and PBX4 Are Differentially Expressed in Acute Lymphoblastic Leukemia: Association of MEIS1 Expression with Higher Proliferation and Chemotherapy Resistance
    Rosales-Avina, Judith A.
    Torres-Flores, Jorge
    Aguilar-Lemarroy, Adriana
    Gurrola-Diaz, Carmen
    Hernandez-Flores, Georgina
    Ortiz-Lazareno, Pablo C.
    Lerma-Diaz, Jose M.
    de Celis, Ruth
    Gonzalez-Ramella, Oscar
    Barrera-Chaires, Esperanza
    Bravo-Cuellar, Alejandro
    Jave-Suarez, Luis F.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2011, 30
  • [29] Are PU.1 mutations major genetic events in acute myeloid leukemia (AML)?
    Preudhomme, C
    Lamandin, C
    Sagot, C
    Roumier, C
    Lepelley, P
    de Boton, S
    Cosson, A
    Fenaux, P
    BLOOD, 2002, 100 (11) : 746A - 746A
  • [30] Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)?
    Lamandin, C
    Sagot, C
    Roumier, C
    Lepelley, P
    De Botton, S
    Cosson, A
    Fenaux, P
    Preudhomme, C
    BLOOD, 2002, 100 (13) : 4680 - 4681